ArticlePloS one2014
Mitochondrial and metabolic dysfunction in renal convoluted tubules of obese mice: protective role of melatonin.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 62 citations in OpenAlex.
- Association of sleep parameters with kidney function: analysis of baseline data from 9216 adults in the Fasa Adult Cohort Study (FACS).Clinical and experimental nephrology · 2025Article
- Transmission electron microscopy ultrastructural characteristics of the distal middle cerebral artery in moyamoya disease.Scientific reports · 2025Article
- Eco-friendly green synthesis of silver nanoparticles from guajava leaves extract for controlling organophosphorus pesticides hazards, characterization, and in-vivo toxicity assessment.BMC pharmacology & toxicology · 2024Article
- Article
- Melatonin Improves Skeletal Muscle Structure and Oxidative Phenotype by Regulating Mitochondrial Dynamics and Autophagy in Zücker Diabetic Fatty Rat.Antioxidants (Basel, Switzerland) · 2023Article
- High-fat diet causes mitochondrial damage and downregulation of mitofusin-2 and optic atrophy-1 in multiple organs.Journal of clinical biochemistry and nutrition · 2023Article
- Protective effect of natural products in the metabolic-associated kidney diseasesFrontiers in pharmacology · 2022Review
- Mitochondrial dynamics and diabetic kidney disease: Missing pieces for the puzzle of therapeutic approaches.Journal of cellular and molecular medicine · 2022Review
- Mechanisms of Melatonin in Obesity: A Review.International journal of molecular sciences · 2021Review
- Renoprotective Effects of Melatonin against Vancomycin-Related Acute Kidney Injury in Hospitalized Patients: a Retrospective Cohort Study.Antimicrobial agents and chemotherapy · 2021Article
- Maternal Melatonin Deficiency Leads to Endocrine Pathologies in Children in Early Ontogenesis.International journal of molecular sciences · 2021Review
- Mammalian Target of Rapamycin Signaling Pathway Regulates Mitochondrial Quality Control of Brown Adipocytes in Mice.Frontiers in physiology · 2021Article
- Melatonin Improves Mitochondrial Dynamics and Function in the Kidney of Zücker Diabetic Fatty Rats.Journal of clinical medicine · 2020Article
- Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2019Article
- Melatonin has profound effects on mitochondrial dynamics in myocardial ischaemia/reperfusion.Heliyon · 2019Article
- NLRP3 Inflammasome Modulation by Melatonin Supplementation in Chronic Pristane-Induced Lupus Nephritis.International journal of molecular sciences · 2019Article
- Diet Modulation Restores Autophagic Flux in Damaged Skeletal Muscle Cells.The journal of nutrition, health & aging · 2019Article
- Perspective: Mitochondria-ER Contacts in Metabolic Cellular Stress Assessed by Microscopy.Cells · 2018Review
- Dietary Melatonin Supplementation Could Be a Promising Preventing/Therapeutic Approach for a Variety of Liver Diseases.Nutrients · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a common and complex health problem, which impacts crucial organs; it is also considered an independent risk factor for chronic kidney disease. Few studies have analyzed the consequence of obesity in the renal proximal convoluted tubules, which are the major tubules involved in reabsorptive processes. For optimal performance of the kidney, energy is primarily provided by mitochondria. Melatonin, an indoleamine and antioxidant, has been identified in mitochondria, and there is considerable evidence regarding its essential role in the prevention of oxidative mitochondrial damage. In this study we evaluated the mechanism(s) of mitochondrial alterations in an animal model of obesity (ob/ob mice) and describe the beneficial effects of melatonin treatment on mitochondrial morphology and dynamics as influenced by mitofusin-2 and the intrinsic apoptotic cascade. Melatonin dissolved in 1% ethanol was added to the drinking water from postnatal week 5-13; the calculated dose of melatonin intake was 100 mg/kg body weight/day. Compared to control mice, obesity-related morphological alterations were apparent in the proximal tubules which contained round mitochondria with irregular, short cristae and cells with elevated apoptotic index. Melatonin supplementation in obese mice changed mitochondria shape and cristae organization of proximal tubules, enhanced mitofusin-2 expression, which in turn modulated the progression of the mitochondria-driven intrinsic apoptotic pathway. These changes possibly aid in reducing renal failure. The melatonin-mediated changes indicate its potential protective use against renal morphological damage and dysfunction associated with obesity and metabolic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.